' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.
Tinhofer, I; Rubenzer, G; Holler, C; Hofstaetter, E; Stoecher, M; Egle, A; Steurer, M; Greil, R;
Blood. 2006; 108(9):2950-2956
Originalarbeiten (Zeitschrift)

PMU-Autor/inn/en

Brachtl Gabriele
Egle Alexander
Greil Richard

Abstract

Chronic lymphocytic leukemia (CLL) is a malignancy mainly affecting elderly people and is still considered an incurable disease. Despite recent advances in CLL treatment, relapse rates are high and often accompanied by the development of resistance towards conventional chemotherapy. Thus, new agents are needed for the treatment of these patients. In recent years, our understanding of the biological mechanisms driving CLL pathogenesis has considerably improved, and novel treatment strategies are arising. This review summarizes recent insights in CLL biology and describes several new agents and treatment strategies that are currently explored in pre-clinical studies and early-phase clinical trials.


Useful keywords (using NLM MeSH Indexing)

Adult

Aged

Aged, 80 and over

Antigens, CD/genetics

Antigens, CD38/genetics*

Female

Gene Expression Regulation/immunology

Humans

Leukemia, Lymphocytic, Chronic, B-Cell/genetics

Leukemia, Lymphocytic, Chronic, B-Cell/immunology*

Lymphocyte Count

Male

Middle Aged

Neoplasm Staging

Sex Characteristics

T-Lymphocytes/immunology*